Faster-acting insulin aspart (NN1218)

:Type 1 and 2 diabetes
:Phase 3

A new formulation of insulin aspart to accelerate onset of action.

Company announcements
The final phase 3a trial for IDegLira completed, and FIAsp approved for phase 3 development (19 Dec 2012)
Read more company announcements

Press releases
No press releases matching the search criteria

Scientific abstracts

No scientific abstracts matching the search criteria

You can search for more clinical trials on